POS-289 A LONG-TERM STUDY TO EVALUATE TENAPANOR'S ABILITY, ALONE OR IN COMBINATION WITH SEVELAMER, TO ACHIEVE NORMAL SERUM PHOSPHORUS IN PATIENTS WITH CKD ON DIALYSIS (NORMALIZE)
D. ROSENBAUM,
A.L. Silva,
Y. Yang,
G. Block
Affiliations
D. ROSENBAUM
Ardelyx Inc., Development, Waltham, United States
A.L. Silva
Boise Kidney and Hypertension Institute, Clinical Research, Boise, United States
Y. Yang
Ardelyx Inc., Biometrics, Fremont, United States
G. Block
US Renal Care, Clinical Research and Medical Affairs, Plano, United States
